Join our daily newsletter At The Bell to receive exclusive market insights
- Zelira Therapeutics (ZLD) completes enrolment for its diabetic nerve pain drug trial
- The trial will evaluate the efficacy and tolerability of Zelira’s proprietary medicinal cannabis product against an undisclosed multi-billion-dollar “big pharmaceutical” company drug
- Zelira says this is a significant milestone for the study, which has been designed as a multi-arm head-to-head comparison of 60 subjects
- Twenty patients in the trial’s investigative drug arm have been enrolled, with results expected by the end of the year
- Zelira Therapeutics shares climb 7.44 per cent, trading at $1.30 at 1:15 pm AEST
Zelira Therapeutics (ZLD) has completed enrolment for its diabetic nerve pain drug trial.
The institutional review board-approved trial will evaluate the efficacy and tolerability of Zelira’s proprietary medicinal cannabis product against an undisclosed multi-billion-dollar “big pharmaceutical” company drug.
Zelira said this was a significant milestone for the trial, which had been designed as a multi-arm head-to-head comparison of 60 subjects, with 20 in each arm.
Zelira Therapeutics CEO and Managing Director Oludare Odumosu said this product trial exemplified Zelira’s strategy to continue generating clinical validation for cannabinoid-based medicines.
“We are very pleased with the rate of recruitment for this clinical trial and look forward to what we hope will be positive results,” Dr Odumosu said.
“The value proposition of Zelira has always been our ‘multiple shots on goal’ strategy that covers both our OTC products and our RX prescription products, that best positions our company for success, and that we continue to deliver on.”
Twenty patients in the trial’s investigative drug arm have already been completely enrolled, with results expected by the end of this year.
Zelira Therapeutics shares climbed 7.44 per cent, trading at $1.30 at 1:15 pm AEST.
